Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

ract # 494P
Date: Monday, October 1
Time: 13:00 – 14:00 PM CESTImpact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after chemotherapy (ctx) and erlotinib (E) or gefitinib (G) – A single center experience

 

Jens Koehler,

MD

ESMO Abstract # 1339
Publication OnlyCombination Afatinib* and Nintedanib*Phase I study of afatinib (BIBW 2992), an ErbB family blocker plus nintedanib (BIBF 1120), a triple angiokinase inhibitor, in patients (pts) with advanced solid tumours

Jean-Charles Soria,

MD, PhD

ESMO Abstract # 446PD
Date: Sunday, September 30
Time: 13:00 – 14:00 PM CESTNintedanib*Phase I study of nintedanib (BIBF 1120) in European patients with advanced hepatocellular carcinoma

Daniel Palmer

ESMO Abstract # 740P
Date: Sunday, September 30
Time: 13:00 – 14:00 PM CESTEarly data from a phase I study of nintedanib (BIBF 1120) in Asian patients with advanced hepatocellular carcinoma

Chia-Jui Yen,

MD, PhD

ESMO Abstract # 744P
Date: Sunday, September 30
Time: 13:00 – 14:00 PM CEST*Afatinib and nintedanib are investigational compounds; their efficacy and safety have not been established.About Boehringer Ingelheim in OncologyBuilding on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.

The current focus of l
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... important devices in spintronics, an electronic which is ... but also on their spin and the spin-related ... into magnetic signals and vice versa. Recently, the ... Institute of Physics at Johannes Gutenberg University Mainz ... and Japan, has for the first time realised ...
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... 2014 Scientists, researchers, and technologists will ... Laser Damage 2014 symposium. Marking its 46th year, ... will run 14-17 September. The event is sponsored by ... . , The premier conference for basic and applied ... optical materials will engage researchers and engineers from numerous ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... is offering a promotion for Eppendorf Safe ... customers to purchase the highest quality tubes at ... are ideal for customers doing chemical, medical, pharmaceutical, ... technicians who are not regularly able to afford ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Year-Over-Year Increase in Revenue; Gross Margin Increase ... Continues; Net Losses ... an innovative medical device company focused on the development of,minimally ... in revenues, cryoprobe sales and procedures and,continued expense reductions in ...
... Vical Incorporated (Nasdaq:,VICL) today announced that the company will ... before the opening of trading on,Thursday, May 8, and ... results and provide a company update at noon Eastern ... a listen-only basis to any interested,parties. The company will ...
... ORCH ), a leading worldwide provider of identity ... results on,Thursday, May 8, 2008 at approximately 7:00 a.m. ... discuss the results at 10:00 a.m. EDT on the,same ... quarter,2008 as well as operating highlights. A question-and-answer session ...
Cached Biology Technology:Endocare Reports 2008 First Quarter Financial Results 2Endocare Reports 2008 First Quarter Financial Results 3Endocare Reports 2008 First Quarter Financial Results 4Endocare Reports 2008 First Quarter Financial Results 5Endocare Reports 2008 First Quarter Financial Results 6Endocare Reports 2008 First Quarter Financial Results 7Endocare Reports 2008 First Quarter Financial Results 8Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results 2Orchid Cellmark to Announce First Quarter 2008 Financial Results on May 8, 2008 2
(Date:8/29/2014)... marine phytoplankton, such as the prolific bloomer Emiliania ... researchers have discovered. The finding contradicts the common view ... microbes depend on scarce supplies of thiamine in the ... to think about the ocean," says CIFAR Senior Fellow ... Journal paper with CIFAR fellows John Archibald ...
(Date:8/28/2014)... A free mobile app called TX Invasives is now ... The University of Texas at Austin for identifying harmful ... , Invasive species in the United States cause about ... they destroy agricultural crops, clog waterways, kill native plants ... TX Invasives app for reporting where invasive species occur, ...
(Date:8/28/2014)... The zebrafish, a ... pattern of blue stripes alternating with golden stripes. Three major ... cells emerge during growth in the skin of the tiny ... the characteristic colour pattern. ,While it was known ... proper stripes, the embryonic origin of the pigment cells that ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... other biological molecules, only exist today in a few ... Tom Ran and Shai Kaplan, research students in the ... Biological Chemistry, and Computer Science and Applied Mathematics Departments ... devices ,user friendly, even while performing complex computations and ...
... 30 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE ... reported financial results for its second quarter ended June 30, 2009. ... quarter of 2009 were $5.8 million, a decrease of 7% compared ... the six months ended June 30, 2009, revenues decreased 14% to ...
... GEOLOGY studies include some curious associations: air hockey and ... Basalts and the Congo Fan; and rock hyrax middens ... on Mars; the only basin known to have both ... fish die-off; and mapping naturally occurring asbestos in the ...
Cached Biology News:DNA computation gets logical at the Weizmann Institute of Science 2Aware, Inc. Reports Second Quarter 2009 Financial Results 2Aware, Inc. Reports Second Quarter 2009 Financial Results 3Aware, Inc. Reports Second Quarter 2009 Financial Results 4Aware, Inc. Reports Second Quarter 2009 Financial Results 5Aware, Inc. Reports Second Quarter 2009 Financial Results 6Aware, Inc. Reports Second Quarter 2009 Financial Results 7Aware, Inc. Reports Second Quarter 2009 Financial Results 8August 2009 Geology and GSA Today media highlights 2August 2009 Geology and GSA Today media highlights 3August 2009 Geology and GSA Today media highlights 4August 2009 Geology and GSA Today media highlights 5August 2009 Geology and GSA Today media highlights 6August 2009 Geology and GSA Today media highlights 7August 2009 Geology and GSA Today media highlights 8August 2009 Geology and GSA Today media highlights 9August 2009 Geology and GSA Today media highlights 10August 2009 Geology and GSA Today media highlights 11August 2009 Geology and GSA Today media highlights 12August 2009 Geology and GSA Today media highlights 13August 2009 Geology and GSA Today media highlights 14August 2009 Geology and GSA Today media highlights 15
Human FADD Affinity Purified Polyclonal Ab...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
... is an inhibitor of ... concentration of inhibitor required ... must be determined empirically ... micromolar inhibitor is sufficient ...
Biology Products: